**OFFICE OF THE ASSISTANT SECRETARY OF DEFENSE**
**HEALTH AFFAIRS**
SKYLINE FIVE, SUITE 810, 5111 LEESBURG PIKE
FALLS CHURCH, VIRGINIA 22041-3206

TRICARE
MANAGEMENT
ACTIVITY

# ADDENDUM TO FEBRUARY 2010 MINUTES FOR DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS

The Pharmacy & Therapeutics Committee evaluated the relative clinical and cost effectiveness of the Antihemophilic Factors at the February 17-18, 2010, meeting. The minutes were subsequently signed by the Director, TRICARE Management Activity (TMA) on May 3, 2010. Following the minutes signing, the Director, TMA, was notified that the Antihemophilic Agent manufacturer Baxter Bioscience has now executed the required Department of Defense (DoD) Retail Refund Pricing Agreement. Therefore, given execution of the required DoD Retail Refund Pricing Agreement and the particular clinical circumstances involved with Antihemophilic Agents, the May 3, 2010 decision is hereby changed as follows: The following Antihemophilic Agents are returned to formulary status on the UF:

- Human Factor VIII: Hemofil M
- Recombinant Factor VIII: Recombinate, Advate
- Prothrombin Complex Concentates: Bebulin VH, Feiba VH

George Peach Taylor, Jr., MD, MPH
Acting Director

11/10/2010
Date